WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205829
CAS#: 1228013-15-7 (free base)
Description: CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. CC-115 binds to and inhibits the activity of DNA-PK and both raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2), which may lead to a reduction in cellular proliferation of cancer cells expressing DNA-PK and TOR. DNA-PK, a serine/threonine kinase and a member of the PI3K-related kinase subfamily of protein kinases, is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks via the DNA nonhomologous end joining (NHEJ) pathway.
MedKoo Cat#: 205829
CAS#: 1228013-15-7 (free base)
Chemical Formula: C16H16N8O
Exact Mass: 336.14471
Molecular Weight: 336.14
Elemental Analysis: C, 57.13; H, 4.79; N, 33.31; O, 4.76
Related CAS #: 1228013-15-7 (free base) 1300118-55-1 (HCl)
Synonym: CC115 ; CC-115; CC 115.
IUPAC/Chemical Name: 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
InChi Key: GMYLVKUGJMYTFB-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-6,8H,3,7H2,1-2H3,(H,17,18)(H,19,20,23)
SMILES Code: O=C1CNC2=NC=C(C3=CC=C(C4=NC=NN4)N=C3C)N=C2N1CC
Appearance: Red Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
|Biological target:||CC-115 is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively, that blocks both mTORC1 and mTORC2 signaling.|
|In vitro activity:||To evaluate the impact of CC-115 inhibition of mTOR kinase and DNA-PK, CC-115 was tested in vitro across a panel of 123 cancer cell lines composed of 40 lymphoma and leukemia, 22 breast cancer, 11 hepatocellular carcinoma, 11 head and neck cancer, and 39 lung cancer cell lines. CC-115 has potent growth inhibitory activity against the majority of the cancer cell lines with GI50 values ranging from 0.015 μM to 1.77 μM (Figure2A2A and Supplementary Table 2). While selective inhibitors of mTOR kinase have been reported to primarily result in cell cycle arrest without significant induction of apoptosis in solid tumor lines, in a subset of both hematological and solid tumor cell lines, CC-115 induced strong apoptosis. CC-115 also inhibited NHEJ activity in a concentrationdependent manner. Partial inhibition was observed with 0.5 μM CC-115 treatment (lane 3) and 5 μM CC-115 achieved complete inhibition (lane 4). Therefore, CC-115 prevents NHEJ by blocking autophosphorylation of DNA-PKcs and dissociation of DNA-PKcs and the ligase IV/XLF/XRCC4 complex from the dsDNA end. This study suggests the use of ATM deficiency as a patient selection strategy for CC-115 as a single agent. Reference: Oncotarget. 2017 Sep 26; 8(43): 74688–74702. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650372/|
|In vivo activity:||The in vivo activity of CC-115 was tested. As described, 786-O cells were s.c. injected into the flanks of the nude mice. Xenografts were established within three weeks (tumor volumes close to 100 mm3, labeled as “Day-0”). The tumor-bearing mice were randomly assigned into three groups, receiving CC-115 or vehicle control. Results demonstrated that oral administration of CC-115, at 2 mg/kg or 5 mg/kg, significantly inhibited subcutaneous 786-O xenograft growth in nude mice (Figure 5A). The estimated daily 786-O tumor growth, calculated by (tumor volume at Day-30 subtracting tumor volume at Day-30)/30, was dramatically inhibited in CC-115treated mice (Figure 5B). Tumors of all three groups were isolated at Day-30 and weighted (Figure 5C). Tumors with CC-115 treatment were much lighter than the vehicle-treated tumors (Figure 5C). The mouse body weights were not significantly different between the three groups (Figure 5D). Collectively, oral administration of CC-115 inhibited subcutaneous 786-O xenograft growth in mice. Reference: Aging (Albany NY). 2020 Oct 31; 12(20): 20445–20456. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655216/|
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 336.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
|Formulation protocol:||1. Tsuji T, Sapinoso LM, Tran T, Gaffney B, Wong L, Sankar S, Raymon HK, Mortensen DS, Xu S. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget. 2017 Aug 18;8(43):74688-74702. doi: 10.18632/oncotarget.20342. PMID: 29088817; PMCID: PMC5650372. 2. Zheng B, Sun X, Chen XF, Chen Z, Zhu WL, Zhu H, Gu DH. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging (Albany NY). 2020 Oct 27;12(20):20445-20456. doi: 10.18632/aging.103847. Epub 2020 Oct 27. PMID: 33109772; PMCID: PMC7655216.|
|In vitro protocol:||1. Tsuji T, Sapinoso LM, Tran T, Gaffney B, Wong L, Sankar S, Raymon HK, Mortensen DS, Xu S. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget. 2017 Aug 18;8(43):74688-74702. doi: 10.18632/oncotarget.20342. PMID: 29088817; PMCID: PMC5650372. 2. Zheng B, Sun X, Chen XF, Chen Z, Zhu WL, Zhu H, Gu DH. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging (Albany NY). 2020 Oct 27;12(20):20445-20456. doi: 10.18632/aging.103847. Epub 2020 Oct 27. PMID: 33109772; PMCID: PMC7655216.|
|In vivo protocol:||1. Zheng B, Sun X, Chen XF, Chen Z, Zhu WL, Zhu H, Gu DH. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging (Albany NY). 2020 Oct 27;12(20):20445-20456. doi: 10.18632/aging.103847. Epub 2020 Oct 27. PMID: 33109772; PMCID: PMC7655216.|
1: Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27. PubMed PMID: 27235137.
2: Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Elsner J, Zhao J, Whitefield B, Tehrani L, Sapienza J, Riggs JR, Parnes JS, Papa P, Packard G, Lee BG, Harris R, Correa M, Bahmanyar S, Richardson SJ, Peng SX, Leisten J, Khambatta G, Hickman M, Gamez JC, Bisonette RR, Apuy J, Cathers BE, Canan SS, Moghaddam MF, Raymon HK, Worland P, Narla RK, Fultz KE, Sankar S. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. J Med Chem. 2015 Jul 23;58(14):5599-608. doi: 10.1021/acs.jmedchem.5b00627. Epub 2015 Jul 8. PubMed PMID: 26102506.
3: Saiz C, Wipf P, Manta E, Mahler G. Reversible thiazolidine exchange: a new reaction suitable for dynamic combinatorial chemistry. Org Lett. 2009 Aug 6;11(15):3170-3. doi: 10.1021/ol901104a. Erratum in: Org Lett. 2010 Jul 16;12(14):3284. PubMed PMID: 19585999; PubMed Central PMCID: PMC2736333.
4: Warheit DB, Hartsky MA, McHugh TA, Kellar KA. Biopersistence of inhaled organic and inorganic fibers in the lungs of rats. Environ Health Perspect. 1994 Oct;102 Suppl 5:151-7. PubMed PMID: 7882921; PubMed Central PMCID: PMC1567301.
CAS#1228013-15-7 (CC-115 free base);
CAS#1300118-55-1 (CC-115 .xHCl salt)